Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1979 2
1980 1
1981 1
1982 7
1983 1
1984 3
1985 4
1986 1
1987 7
1988 7
1989 13
1990 8
1991 5
1992 11
1993 8
1994 9
1995 9
1996 19
1997 18
1998 6
1999 18
2000 6
2001 12
2002 9
2003 14
2004 15
2005 13
2006 8
2007 10
2008 9
2009 9
2010 7
2011 7
2012 11
2013 11
2014 16
2015 13
2016 8
2017 8
2018 7
2019 14
2020 10
2021 6
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

374 results
Results by year
Filters applied: . Clear all Your search was processed without automatic term mapping because it retrieved zero results. The following term was not found in PubMed: Keani
Page 1
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators. Peyvandi F, et al. N Engl J Med. 2016 Feb 11;374(6):511-22. doi: 10.1056/NEJMoa1505533. N Engl J Med. 2016. PMID: 26863353 Free article. Clinical Trial.
BACKGROUND: Acquired thrombotic thrombocytopenic purpura (TTP) is caused by aggregation of platelets on ultralarge von Willebrand factor multimers. This microvascular thrombosis causes multiorgan ischemia with potentially life-threatening complications. Daily plasma exchan …
BACKGROUND: Acquired thrombotic thrombocytopenic purpura (TTP) is caused by aggregation of platelets on ultralarge von Willebrand fac …
Targeted antibody and cytokine cancer immunotherapies through collagen affinity.
Ishihara J, Ishihara A, Sasaki K, Lee SS, Williford JM, Yasui M, Abe H, Potin L, Hosseinchi P, Fukunaga K, Raczy MM, Gray LT, Mansurov A, Katsumata K, Fukayama M, Kron SJ, Swartz MA, Hubbell JA. Ishihara J, et al. Sci Transl Med. 2019 Apr 10;11(487):eaau3259. doi: 10.1126/scitranslmed.aau3259. Sci Transl Med. 2019. PMID: 30971453 Free PMC article.
Here, we addressed this need by targeting both the CPI antibodies anti-cytotoxic T lymphocyte antigen 4 antibody (alphaCTLA4) + anti-programmed death ligand 1 antibody (alphaPD-L1) and the cytokine IL-2 to tumors via conjugation (for the antibodies) or recombinant fusion (for the …
Here, we addressed this need by targeting both the CPI antibodies anti-cytotoxic T lymphocyte antigen 4 antibody (alphaCTLA4) + anti-program …
Management of bleeding disorders in adults.
Peyvandi F, Klamroth R, Carcao M, Federici AB, DI Minno G, Jiménez-Yuste V, Rodriguez Merchán EC. Peyvandi F, et al. Haemophilia. 2012 May;18 Suppl 2:24-36. doi: 10.1111/j.1365-2516.2012.02797.x. Haemophilia. 2012. PMID: 22530576 Review.
In this section we will review some important aspects of the management of haemophilia in adults, including an overview of bleeding in women with von Willebrand disease, an analysis of FVIII consumption in patients with severe haemophilia A, an update of the ongoing RES.I. …
In this section we will review some important aspects of the management of haemophilia in adults, including an overview of bleeding in women …
Distribution and biomarkers of carbon-14-labeled fullerene C60 ([(14) C(U)]C60 ) in female rats and mice for up to 30 days after intravenous exposure.
Sumner SC, Snyder RW, Wingard C, Mortensen NP, Holland NA, Shannahan JH, Dhungana S, Pathmasiri W, Han L, Lewin AH, Fennell TR. Sumner SC, et al. J Appl Toxicol. 2015 Dec;35(12):1452-64. doi: 10.1002/jat.3110. Epub 2015 Feb 27. J Appl Toxicol. 2015. PMID: 25727383 Free PMC article.

The highest concentration of radioactivity in rodents at each time point was in liver, lungs and spleen. Elimination of [(14) C(U)]C60 was < 2% in urine and feces at any 24 h time points. [(14) C(U)]C60 and [(14) C(U)]C60 -retinol were

The highest concentration of radioactivity in rodents at each time point was in liver, lungs and spleen. Elimination of [(14) C(U
Dysregulation of Amphiregulin stimulates the pathogenesis of cystic lymphangioma.
Yoshida N, Yamamoto S, Hamashima T, Okuno N, Okita N, Horikawa S, Hayashi M, Dang TC, Nguyen QL, Nishiyama K, Makino T, Ishii Y, Tomihara K, Shimizu T, Shibuya M, Noguchi M, Sasahara M. Yoshida N, et al. Proc Natl Acad Sci U S A. 2021 May 11;118(19):e2019580118. doi: 10.1073/pnas.2019580118. Proc Natl Acad Sci U S A. 2021. PMID: 33941693 Free PMC article.
Postnatal lymphangiogenesis commonly occurs from preexisting lymphatic vessels by sprouting, which is induced by lymphangiogenic factors such as vascular endothelial growth factor C (VEGF-C). However, the key signals and cell types that stimulate pathological lympha …
Postnatal lymphangiogenesis commonly occurs from preexisting lymphatic vessels by sprouting, which is induced by lymphangiogenic factors suc …
Replacement Therapy in Patients with Von Willebrand Disease-Indications and Monitoring.
Nowak-Göttl U, Miesbach W, Koscielny J, Dempfle CE, Maegele M, Prondzinski MVD, Westrup D, Spannagl M. Nowak-Göttl U, et al. Hamostaseologie. 2019 Nov;39(4):326-338. doi: 10.1055/s-0039-1692688. Epub 2019 Jul 30. Hamostaseologie. 2019. PMID: 31364093 Review. English.
The deficient von Willebrand factor (VWF) is replaced with or without factor VIII (FVIII). Dual VWF/FVIII concentrates can be beneficial in the case of low FVIII level, while repeated dosing may lead to very high FVIII levels, with a potential thrombogenic effect in indivi …
The deficient von Willebrand factor (VWF) is replaced with or without factor VIII (FVIII). Dual VWF/FVIII concentrates can be benefic …
Thrombomodulin is essential for maintaining quiescence in vascular endothelial cells.
Giri H, Panicker SR, Cai X, Biswas I, Weiler H, Rezaie AR. Giri H, et al. Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):e2022248118. doi: 10.1073/pnas.2022248118. Proc Natl Acad Sci U S A. 2021. PMID: 33836597 Free PMC article.
Thrombomodulin (TM) is a thrombin receptor on endothelial cells that is involved in promoting activation of the anticoagulant protein C pathway during blood coagulation. TM also exerts protective anti-inflammatory properties through a poorly understood mechanism. ...There …
Thrombomodulin (TM) is a thrombin receptor on endothelial cells that is involved in promoting activation of the anticoagulant protein C
Overview of Blood Coagulation.
Green D. Green D. Hemodial Int. 2001 Jan;5(1):70-73. doi: 10.1111/hdi.2001.5.1.70. Hemodial Int. 2001. PMID: 28452438 Review.
When the integrity of the endothelium is breached, vasoconstriction occurs through neural and chemical (endothelin, thromboxane) mechanisms, and platelet adhesion is facilitated (von Willebrand factor). Activation of platelets accompanied by microparticle formation provide …
When the integrity of the endothelium is breached, vasoconstriction occurs through neural and chemical (endothelin, thromboxane) mechanisms, …
Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function.
Meyer D, Fressinaud E, Hilbert L, Ribba AS, Lavergne JM, Mazurier C. Meyer D, et al. Best Pract Res Clin Haematol. 2001 Jun;14(2):349-64. doi: 10.1053/beha.2001.0137. Best Pract Res Clin Haematol. 2001. PMID: 11686104 Review.
Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function comprises mainly subtypes 2A, 2B and 2M. ...In type 2A disease, molecular abnormalities identified in the A2 domain, which contains a specific proteolytic site, are ass …
Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function comprises mainly subtypes 2A …
von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality.
Catto AJ, Carter AM, Barrett JH, Bamford J, Rice PJ, Grant PJ. Catto AJ, et al. Thromb Haemost. 1997 Jun;77(6):1104-8. Thromb Haemost. 1997. PMID: 9241740
Levels of vWF and FVIII:C were elevated initially (1.86 IU/ml and 2.20 U/ml respectively) and after 3 months (1.51 IU/ml and 1.90 U/ml) compared with a healthy reference population (1.26 IU/ml and 1.49 U/ml p = 0.0001). In the initial sample, vWF was a …
Levels of vWF and FVIII:C were elevated initially (1.86 IU/ml and 2.20 U/ml respectively) and after 3 months (1.51 IU/ml and 1 …
374 results